Results 201 to 210 of about 677,503 (281)

Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs. [PDF]

Oncologist, 2019
Kiesewetter B, Duan H, Lamm W, Haug A, Riss P, Selberherr A, Scheuba C, Raderer M.   +7 more
europepmc   +1 more source

Corrigendum: Estrogens modulate somatostatin receptors expression and synergize with the somatostatin analog pasireotide in prostate cells

Frontiers in Pharmacology
Valentina Rossi, Erika Di Zazzo, Giovanni Galasso, Caterina De Rosa, Ciro Abbondanza, Antonio A. Sinisi, Lucia Altucci, Antimo Migliaccio, Gabriella Castoria   +8 more
doaj   +1 more source

Somatostatin and its analogs in the management of postoperative pancreatic fistulas: A comprehensive review. [PDF]

World J Gastrointest Surg
Lazaridou L, Dimaki A, Vakalou K, Zervas V, Papadopoulos P, Koumarelas KE, Christodoulidis G.   +6 more
europepmc   +1 more source

Recurrent ventricular asystole during octreotide infusion in a patient with pancreatic neuroendocrine tumor: a case report. [PDF]

J Med Case Rep
Mansolas N, Nesbitt I.
europepmc   +1 more source

Acromegaly: Treatment with somatostatin analogs

, 2016
Karavitaki, N, Wass, J
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Somatostatin and its Analogs

Current Drug Targets, 2016
Somatostatin (SST) is a cyclic hormone-release inhibitory peptide that has high binding affinity to all of its five SST receptors (SSTRs). SST negatively regulates cell proliferation and the release of multiple hormones via activation of its cognate receptors.
Lichun, Sun, David H, Coy
openaire   +3 more sources

Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in the Biology of Cancer Progression

Current Molecular Medicine, 2013
The pharmacological effects (i.e., inhibition of endocrine secretion and cell proliferation) mediated by the hormone somatostatin (SRIF) are derived from its universal high-affinity binding to five different G proteincoupled receptors (GPCRs), named sst1-5.
Ruscica M, ARVIGO, MARICA, Steffani L, FERONE, DIEGO, Magni P.   +4 more
openaire   +5 more sources

Response and relapse rates after treatment with long‐acting somatostatin analogs in multifocal or recurrent type‐1 gastric carcinoids: A systematic review and meta‐analysis

United European Gastroenterology Journal, 2020
Background Type-1 gastric neuroendocrine tumors represent a recurring disease and long-acting somatostatin analogs can inhibit both gastrin release and endocrine cell proliferation. The efficacy and timing of this treatment are still unclear.
Roberta Elisa Rossi, Pietro Invernizzi, Vincenzo Mazzaferro   +2 more
exaly   +2 more sources

Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects

Expert Opinion on Pharmacotherapy, 2017
Gherardo Mazziotti, Alessandra Mosca, Stefano Frara   +2 more
exaly   +2 more sources

Adverse events associated with somatostatin analogs in acromegaly

Expert Opinion on Drug Safety, 2015
Rosario Pivonello
exaly   +2 more sources